Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPGbio Receives FDA Pediatric Disease Designation for Epidermolysis Bullosa Treatment
Details : BPM31510T (benzoquinone ubidecarenone) is an investigational treatment for epidermolysis bullosa (EB), received Rare Pediatric Disease Designation for respective indication.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
October 31, 2024
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzoquinone Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPGbio Gets FDA Pediatric Designation for Coenzyme Q10 Deficiency Drug
Details : BPM31510IV (benzoquinone ubidecarenone) works by restoring CoQ10 levels which can overcome the effect of mutations in genes that lead to mitochondrial dysfunction, in primary CoQ10 deficiency.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Benzoquinone Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
BPGbio and University of Oxford Partner on E2-Based Protein Degradation Research
Details : The collaboration aims to develop novel protein degraders to deliver groundbreaking therapeutic candidates for particularly in oncology and central nervous system (CNS) diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Berg Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Berg Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Debra of America
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Ubidecarenone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Debra of America
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 26, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Recipient : Shasa Hu
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
June 08, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Recipient : Shasa Hu
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 08, 2016
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 01, 2015
Lead Product(s) : Coenzyme Q10
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable